The clinical outcome in cancer treatment has significantly improved in some patient cohorts since immune-checkpoint inhibitors (ICIs) are used in the clinics, like those targeting the PD-1/PD-L1 and CTLA-4 axes. This evidence concerns the gene CD274 and cancer.